Profile data is unavailable for this security.
About the company
Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.
- Revenue in CAD (TTM)328.20m
- Net income in CAD-16.84m
- Incorporated2015
- Employees725.00
- LocationKnight Therapeutics Inc3400 De Maisonneuve Blvd WMONTREAL H3Z 3B8CanadaCAN
- Phone+1 (514) 484-4483
- Fax+1 (514) 481-4116
- Websitehttps://www.gud-knight.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aurora Cannabis Inc | 266.97m | -125.07m | 533.94m | 1.13k | -- | 0.9021 | -- | 2.00 | -3.39 | -3.63 | 6.83 | 10.85 | 0.29 | 1.96 | 6.57 | 236,259.30 | -14.60 | -- | -17.65 | -- | 1.93 | -- | -50.34 | -- | 2.45 | -23.12 | 0.1562 | -- | -- | -- | -- | -- | -- | -- |
| Knight Therapeutics Inc | 328.20m | -16.84m | 580.44m | 725.00 | -- | 0.7748 | 17.29 | 1.77 | -0.163 | -0.163 | 3.05 | 7.38 | 0.3282 | 1.90 | 3.57 | 452,688.30 | -1.68 | 0.3477 | -1.93 | 0.4156 | 46.51 | 46.28 | -5.13 | 1.69 | 2.40 | 0.2221 | 0.0847 | 0.00 | 11.80 | 92.24 | 43.68 | -- | 20.79 | -- |
| Terrascend Corp | 434.74m | -124.81m | 657.20m | 742.00 | -- | 2.38 | -- | 1.51 | -0.4452 | -0.4678 | 1.56 | 0.9443 | 0.4639 | 3.22 | 29.23 | -- | -12.03 | -28.09 | -16.09 | -36.19 | 50.33 | 46.65 | -25.93 | -69.16 | 0.2474 | 0.9394 | 0.4648 | -- | 28.04 | 126.98 | 70.03 | -- | -0.8878 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Gestion de Portefeuille Strat�gique Medici, Inc.as of 29 Feb 2024 | 12.97m | 12.82% |
| QV Investors, Inc.as of 29 Feb 2024 | 4.97m | 4.91% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 2.28m | 2.25% |
| Fidelity Investments Canada ULCas of 31 Jan 2024 | 1.60m | 1.58% |
| COTE 100, Inc.as of 31 Dec 2023 | 794.00k | 0.79% |
| Bessemer Investment Management LLCas of 31 Jan 2024 | 411.03k | 0.41% |
| 1832 Asset Management LPas of 31 Dec 2023 | 398.70k | 0.39% |
| North Growth Management Ltd.as of 31 Dec 2023 | 325.57k | 0.32% |
| CI Investments, Inc.as of 30 Jun 2023 | 302.89k | 0.30% |
| Royce & Associates LPas of 31 Mar 2024 | 237.00k | 0.23% |
